KRT‑232: first-in-class MDM2I for myelofibrosis R/R to JAK inhibitor therapy
Haifa Kathrin Al-Ali
Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Keep up to date with all the latest news with our monthly newsletter